Dyadic International, Inc. (DYAI)

NASDAQ: DYAI · IEX Real-Time Price · USD
1.28
-0.04 (-3.03%)
Dec 9, 2022 3:50 PM EST - Market closed
-3.03%
Market Cap 37.70M
Revenue (ttm) 2.50M
Net Income (ttm) -11.80M
Shares Out 28.39M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE 13.64
Dividend n/a
Ex-Dividend Date n/a
Volume 33,279
Open 1.3
Previous Close 1.32
Day's Range 1.27 - 1.31
52-Week Range 1.27 - 4.98
Beta 0.39
Analysts Buy
Price Target 7.65 (+497.7%)
Earnings Date Nov 10, 2022

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therape... [Read more]

Industry Biotechnology
IPO Date Nov 5, 2004
Employees 7
Stock Exchange NASDAQ
Ticker Symbol DYAI
Full Company Profile

Financial Performance

In 2021, DYAI's revenue was $2.40 million, an increase of 50.06% compared to the previous year's $1.60 million. Losses were -$13.07 million, 40.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for DYAI stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 497.66% from the latest price.

Price Target
$7.65
(497.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

JUPITER, Fla., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative ...

4 weeks ago - GlobeNewsWire

Dyadic to Present at Upcoming Industry and Investor Events in November

JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms...

1 month ago - GlobeNewsWire

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative ...

1 month ago - GlobeNewsWire

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in...

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative ...

1 month ago - GlobeNewsWire

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipelin...

JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms...

2 months ago - GlobeNewsWire

Dyadic Updates Market on Recent Scientific Achievements

JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platform...

2 months ago - GlobeNewsWire

Dyadic to Present at Upcoming Industry and Investor Events in September

JUPITER, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platform...

3 months ago - GlobeNewsWire

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

JUPITER, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative ...

3 months ago - GlobeNewsWire

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

JUPITER, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, a...

4 months ago - GlobeNewsWire

Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting

JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deployi...

5 months ago - GlobeNewsWire

Dyadic to Participate in Three Upcoming Industry Events

JUPITER, Fla., June 09, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deployi...

6 months ago - GlobeNewsWire

Dyadic to Present at 2022 Jefferies Healthcare Conference

JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deployi...

6 months ago - GlobeNewsWire

Dyadic to Present at H.C. Wainwright Global Investment Conference

JUPITER, Fla., May 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying...

6 months ago - GlobeNewsWire

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

JUPITER, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ap...

6 months ago - GlobeNewsWire

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ap...

6 months ago - GlobeNewsWire

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

JUPITER, Fla., May 09, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on deploying its proprie...

7 months ago - GlobeNewsWire

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...

7 months ago - GlobeNewsWire

Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic's Licensed ...

JUPITER, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced today that Dyadic Li...

7 months ago - GlobeNewsWire

Dyadic International to Present at Upcoming Scientific Medical Meetings

JUPITER, Fla., April 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deployi...

8 months ago - GlobeNewsWire

Dyadic Reports 2021 Year End Results and Recent Company Progress

JUPITER, Fla., March 29, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...

8 months ago - GlobeNewsWire

Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...

8 months ago - GlobeNewsWire

Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.

9 months ago - Zacks Investment Research

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targe...

9 months ago - GlobeNewsWire

Dyadic International's CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deployin...

10 months ago - GlobeNewsWire

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Pla...

JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, a...

10 months ago - GlobeNewsWire